TAPO in first‐line osimertinib therapy and continuation of osimertinib
Abstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14782 |
| _version_ | 1797894372713299968 |
|---|---|
| author | Chihiro Mimura Kazumi Kaneshiro Shodai Fujimoto Ryota Dokuni Natsuhiko Iwamoto Kanoko Matsumura Yukihisa Hatakeyama Yuko Kono Motoko Tachihara |
| author_facet | Chihiro Mimura Kazumi Kaneshiro Shodai Fujimoto Ryota Dokuni Natsuhiko Iwamoto Kanoko Matsumura Yukihisa Hatakeyama Yuko Kono Motoko Tachihara |
| author_sort | Chihiro Mimura |
| collection | DOAJ |
| description | Abstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and the pros and cons of osimertinib continuation is unknown. Methods This was a multicenter, retrospective study. The purpose of this study was to research the frequency of TAPO and to evaluate osimertinib continuation in first‐line therapy. We also evaluated progression‐free survival (PFS) including subgroup analysis. Results From August 2018 to December 2020, 133 patients were enrolled into the study. The median observation period was 23.2 months (0.3–48.3 months). Thirty patients (22.6%) experienced D‐ILD events, including 16 patients (12.1%) with CTCAE grade 1, five patients (3.8%) with grade 2, and nine patients (6.7%) with grade 3 and above D‐ILD. Among the patients with grade 1 D‐ILD, 11 cases (8.3%) of TAPO were observed, and all patients succeeded in osimertinib continuation. The TAPO images were characterized by localized patchy opacities (73%). The median PFS was 22.6 months (95% confidence interval [CI]: 17.8–28.7 months). Patients with TAPO had a significantly longer PFS than patients with non‐TAPO D‐ILD in the multivariate analysis. Conclusions This study showed that grade 1 D‐ILD might include TAPO and that patients with TAPO might have good PFS. We need to consider the possibility of osimertinib continuation when lung opacities appear. |
| first_indexed | 2024-04-10T07:07:57Z |
| format | Article |
| id | doaj.art-08f25ea72cab40159dd7263d20e634f6 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-10T07:07:57Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-08f25ea72cab40159dd7263d20e634f62023-02-27T01:36:59ZengWileyThoracic Cancer1759-77061759-77142023-02-0114658459110.1111/1759-7714.14782TAPO in first‐line osimertinib therapy and continuation of osimertinibChihiro Mimura0Kazumi Kaneshiro1Shodai Fujimoto2Ryota Dokuni3Natsuhiko Iwamoto4Kanoko Matsumura5Yukihisa Hatakeyama6Yuko Kono7Motoko Tachihara8Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDepartment of Respiratory Medicine Kita‐Harima Medical Center Ono‐City JapanDivision of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe JapanDepartment of Respiratory Medicine Hyogo Prefectural Awaji Medical Center Sumoto JapanDepartment of Respiratory Medicine Takatsuki General Hospital Osaka JapanDepartment of Respiratory Medicine Takatsuki General Hospital Osaka JapanDepartment of Respiratory Medicine Akashi Medical Center Akashi JapanDepartment of Respiratory Medicine Kita‐Harima Medical Center Ono‐City JapanDivision of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe JapanAbstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and the pros and cons of osimertinib continuation is unknown. Methods This was a multicenter, retrospective study. The purpose of this study was to research the frequency of TAPO and to evaluate osimertinib continuation in first‐line therapy. We also evaluated progression‐free survival (PFS) including subgroup analysis. Results From August 2018 to December 2020, 133 patients were enrolled into the study. The median observation period was 23.2 months (0.3–48.3 months). Thirty patients (22.6%) experienced D‐ILD events, including 16 patients (12.1%) with CTCAE grade 1, five patients (3.8%) with grade 2, and nine patients (6.7%) with grade 3 and above D‐ILD. Among the patients with grade 1 D‐ILD, 11 cases (8.3%) of TAPO were observed, and all patients succeeded in osimertinib continuation. The TAPO images were characterized by localized patchy opacities (73%). The median PFS was 22.6 months (95% confidence interval [CI]: 17.8–28.7 months). Patients with TAPO had a significantly longer PFS than patients with non‐TAPO D‐ILD in the multivariate analysis. Conclusions This study showed that grade 1 D‐ILD might include TAPO and that patients with TAPO might have good PFS. We need to consider the possibility of osimertinib continuation when lung opacities appear.https://doi.org/10.1111/1759-7714.14782interstitial lung diseaselung cancerNSCLCtransient asymptomatic pulmonary opacity (TAPO) |
| spellingShingle | Chihiro Mimura Kazumi Kaneshiro Shodai Fujimoto Ryota Dokuni Natsuhiko Iwamoto Kanoko Matsumura Yukihisa Hatakeyama Yuko Kono Motoko Tachihara TAPO in first‐line osimertinib therapy and continuation of osimertinib Thoracic Cancer interstitial lung disease lung cancer NSCLC transient asymptomatic pulmonary opacity (TAPO) |
| title | TAPO in first‐line osimertinib therapy and continuation of osimertinib |
| title_full | TAPO in first‐line osimertinib therapy and continuation of osimertinib |
| title_fullStr | TAPO in first‐line osimertinib therapy and continuation of osimertinib |
| title_full_unstemmed | TAPO in first‐line osimertinib therapy and continuation of osimertinib |
| title_short | TAPO in first‐line osimertinib therapy and continuation of osimertinib |
| title_sort | tapo in first line osimertinib therapy and continuation of osimertinib |
| topic | interstitial lung disease lung cancer NSCLC transient asymptomatic pulmonary opacity (TAPO) |
| url | https://doi.org/10.1111/1759-7714.14782 |
| work_keys_str_mv | AT chihiromimura tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT kazumikaneshiro tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT shodaifujimoto tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT ryotadokuni tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT natsuhikoiwamoto tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT kanokomatsumura tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT yukihisahatakeyama tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT yukokono tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib AT motokotachihara tapoinfirstlineosimertinibtherapyandcontinuationofosimertinib |